Latest Revenue Growth News

LGI Limited reports a solid H1 FY25 performance with modest revenue growth and increased EBITDA, driven by expanded biogas flows and carbon abatement activities. The company confirms a positive outlook with a 12-15% underlying EBITDA growth forecast for FY25.

Westgold Resources reports a sharp revenue increase driven by higher gold prices and the Karora acquisition, yet posts a net loss for the half-year ending December 2024. The company also declares a fully franked dividend amid rising costs.

LGI Limited reported a 7% rise in revenue and a 3% increase in EBITDA for H1 FY25, driven by expanded power generation capacity and higher landfill gas flows. However, net profit after tax declined by 22%, reflecting ongoing investment and market dynamics.

Abacus Storage King reported a modest 1.1% increase in statutory profit for HY25, underpinned by resilient operating metrics and a robust balance sheet. The company’s multi-pronged growth strategy, including acquisitions and a substantial development pipeline, supports a confident outlook with reaffirmed distribution guidance.

Abacus Storage King reported a striking turnaround with a $67.8 million net profit for H1 2024, up from just $0.4 million a year earlier, alongside a raised interim distribution reflecting robust growth in the self-storage sector.

Mirvac Group reports a 2% revenue increase and a remarkable 100% rise in profit attributable to stapled securityholders for H1 2024, even as operating profit after tax declines by 6%.

GQG Partners delivered robust full-year 2024 results, marked by a 26.9% increase in funds under management and nearly 47% growth in net revenue, underpinned by strong investment performance and strategic initiatives including Private Capital Solutions and a new Abu Dhabi office.

GQG Partners Inc. reported strong financial results for 2024, with significant increases in revenue, net income, and funds under management, alongside a raised dividend and strategic moves including the deconsolidation of its PCS Master Fund.

AVITA Medical reported a strong 30% increase in Q4 2024 commercial revenue and amended its credit agreement with OrbiMed to adjust revenue covenants through 2026. The company is poised for significant growth with new product rollouts and expects profitability by year-end 2025.

AVITA Medical's Q4 2024 earnings reveal strong commercial growth alongside the launch of Cohealyx, a novel collagen-based skin substitute that promises to transform acute wound care.

AVITA Medical reported a robust 30% increase in Q4 2024 commercial revenue alongside key FDA clearances, setting the stage for ambitious growth in 2025.

Civmec’s 1H FY25 results reveal robust revenue growth and a strong balance sheet, underpinned by a diversified project pipeline and strategic moves into naval shipbuilding and material handling equipment manufacturing.